EP 9001A
Alternative Names: EP-9001ALatest Information Update: 18 Apr 2022
At a glance
- Originator Easton Biopharmaceuticals
- Class Monoclonal antibodies; Non-opioid analgesics
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer pain; Neuropathic pain
Most Recent Events
- 18 Apr 2022 Phase-I clinical trials in Cancer pain (In volunteers) in China (SC) (NCT05278611)
- 23 Mar 2022 Phase-I clinical trials in Neuropathic pain (In volunteers) in China (SC) (NCT05278611)
- 20 Mar 2022 Preclinical trials in Cancer pain in China (SC) (Chengdu Easton Biopharmaceuticals pipeline, March 2022)